SCHEMBL3760552

SCHEMBL3760552

COc1ccc(-c2noc(-c3nnn(-c4ccccc4F)c3-c3ccncc3)n2)cn1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.45
TP53 P04637 7/20 0.42
RAB9A P51151 8/20 0.40
NPC1 O15118 8/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 6/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
HSD11B1 P28845 1/20 0.36
CYP19A1 P11511 1/20 0.36
EPHB4 P54760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10181614 0.88 S1PR1 (0.47) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3478080 0.87 NPC1 (0.54) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3750323 0.86 S1PR1 (0.45) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3761084 0.86 NPC1 (0.54) S1PR1TP53RAB9ANPC1PKM
SCHEMBL10181634 0.85 S1PR1 (0.46) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3761370 0.85 S1PR1 (0.46) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3753060 0.84 S1PR1 (0.49) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3760882 0.84 NPC1 (0.51) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3755430 0.84 NPC1 (0.50) S1PR1TP53RAB9ANPC1PKM
SCHEMBL3760855 0.84 NPC1 (0.52) S1PR1TP53RAB9ANPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
EP-2250165-B1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2018-07-25 EP disclosed
CN-101918395-B Triazole oxadiazole derivatives MERCK SERONO SA 2014-04-16 CN disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202856-B2 Triazole oxadiazoles derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO SA (CH) 2010-12-02 US disclosed
WO-2009080663-A1 TRIAZOLE OXADIAZOLES DERIVATIVES MERCK SERONO S.A. (CH) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305092-A1 TRIAZOLE OXADIAZOLES DERIVATIVES OXA1L, RO60, PDCD11 S1PR1 517/4885TP53 2220/4885RAB9A 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.